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Cytotoxic antineoplastic drugs (ADs) pose occupational risk and therefore require safe handling practices. We created, 
optimised, and validated an innovative monitoring protocol for simultaneously assessing 21 ADs in the healthcare 
environment, and also proposed surface exposure levels (SELs) to facilitate the interpretation of monitoring results, as 
there are currently no occupational exposure limits for ADs. The environmental AD monitoring data were collected in 
nine Italian hospitals between 2008 and 2017 and include 74,565 measurements in 4,814 wipe samples. Excellent overall 
recovery and sensitivity of the analytical methods along with innovative desorption automation make this protocol useful 
for routine monitoring. AD contamination was found in 3,081 measurements, confirming potential exposure in healthcare 
workers. Samples taken at the beginning and the end of work shifts, allowed to calculate 75th and 90th percentile values 
for each ADs both in preparation and administration units and we created a traffic-light colour-coding system to facilitate 
interpretation of the findings. The introduction of SELs will provide a solid basis for improving occupational safety and 
focusing on contamination control.
KEY WORDS: inductively coupled plasma mass spectrometry; liquid chromatography-mass spectrometry; surface 
contamination; wipe test; workplace safety
According to the World Cancer Research Fund 
International (1), the age-standardised rate for all cancers 
in men and women combined was 182 people per 100,000 
in 2012, and in 2035, there will be around 24 million new 
cases of cancer around the world. Pacific Asia has been 
identified as a rather lucrative region for the anti-cancer 
drug market owing to the rising awareness of the availability 
of advanced therapies (2). In China, nearly four million new 
tumour cases appear every year, and by 2021, the total 
output of cytotoxic drugs is expected to reach 1,000 tonnes 
(3) with an estimated compound annual growth rate between 
7.1 % and 7.4 % of the global market (4, 5). Furthermore, 
antineoplastic drugs (ADs) like cyclophosphamide (CP) 
and methotrexate (MT) have proved beneficial against non-
malignant diseases too, such as rheumatoid arthritis and 
multiple sclerosis, and their use is expected only to increase.
The National Institute for Occupational Safety and 
Health (NIOSH) (6) has recently released its updated list 
of hazardous drugs and has estimated that millions of 
healthcare workers – those who prepare and administer 
these medications to patients with cancer and other 
conditions – run the risk of exposure to these hazardous 
drugs at their workplace. The list includes chemotherapy 
drugs, many of which are mutagenic and carcinogenic (7). 
Concerns about occupational exposure to ADs were first 
expressed in the 1970s, and studies continue to evidence 
healthcare worker susceptibility. Ratner et al. (8) reported 
higher risk of breast cancer and reproductive health effects 
in nurses employed in oncology units. Hall et al. (9) show 
that about 75,000 Canadians – 0.42 % of the total workforce 
– are occupationally exposed to ADs, 75 % of whom are 
women. In Italy, of the 331 oncology wards surveyed, 256 
have a centralised antineoplastic drug (AD) preparation 
unit, employing a total of 7,000 operators (10). As the usage 
and number of these drugs increase, so do opportunities for 
exposures (11).
The basic occupational health approach to minimising 
exposure risks combines several industrial hygiene control 
methods in a specific order or hierarchy. One of these 
methods, environmental monitoring, enables us to pinpoint 
contamination trends, identify corrective measures, and 
increase workers’ awareness. In the case of cytotoxic ADs, 
monitoring surface contamination in hospital environments 
usually involves wipe tests as a simple way to indirectly 
assess dermal occupational exposure (12). However, most 
of the monitoring (13-20) is focused on no more than five 
ADs among the following drugs: CP, MT, iphosfamide (IP), 
paclitaxel (PTX), doxorubicin (DXR), 5-fluorouracyl (5-
FU), docetaxel (DTX), epirubicin (EPI), and gemcitabine 
(GEM). Only a few (21-23) have expanded the range from 
seven to ten [5-FU, PTX, CP, IP, MT, GEM, DXR, EPI, 
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vincristine (VNC), vinblastine (VNB), docetaxel (DTX), 
etoposide (ETP), cytarabine (CTB), irinotecan (IRT), 
oxaliplatin, and vindesine].
Yet, no occupational exposure limits exist for ADs in 
any work environment. Sessink (24) proposed CP reference 
values for a traffic-light colour-coding model that would 
help interpret the findings in terms of exposure risk, where 
green is safe, amber alerting, and red means high risk. 
Kiffmeyer et al. (22), instead, produced a substance-
independent guideline based on the 90th percentile values 
of eight ADs (CP, DTX, ETP, 5-FU, GEM, IP, MT, and 
PTX). Stricter Threshold Guidance Values (TGVs) for 
platinum (Pt) and 5-FU, such as the 50th or 75th percentile, 
have been suggested by Schierl et al. (25) and Böhlandt and 
Schierl (26). In addition, Hedmer et al. (27) put forward 
Hygienic Guidance Values (HGVs) for CP and IP for 
different categories of surfaces at hospital workplaces. Most 
recently, Sottani et al. (28) have recommended HGVs for 
four ADs based on the 90th percentile of wipe-sampling data 
distributions.
In the present work we propose our innovative surface 
monitoring protocol for multiple classes of ADs, while, at 
the same time, automating and standardising the procedure 
to considerably decrease the time needed for sample 
preparation and analysis. In addition, we propose surface 
exposure levels (SELs) for twenty-one ADs.
MATERIALS AND METHODS
Experimental design
To evaluate AD contamination of work surfaces, we 
evaluated 4,814 wipes (Table 1) from nine hospitals located 
in the northern, central, and southern Italy from 2008 to 
2017. Sampling included 9 cytostatic preparation and 17 
administration units. The volume of AD administrations 
ranged from 18,011 to 48,086 per hospital per year. Hospital 
programs followed the Italian guidelines (G.U. 236, 
7.10.1999), specifically: i) staff were trained and re-trained 
in safety equipment and maintenance, research updates, and 
emergency care); ii) closed system devices were used for 
drug transfer between preparation and administration units 
to prevent any escape of hazardous drugs (ChemoClave, 
ICU Medical Inc., San Clemente, USA; CareFusion, Becton 
Dickinson, Franklin Lakes, USA; Cyto-Set, B-Braun, 
Milan, Italy); and iii) specific cleaning products were 
utilised for floors (0.2 % Marseille soap solution, 0.115 % 
sodium hypochlorite, and 70 % ethanol, in this order) and 
for small surfaces (Alcavis Bleach-Wipe 1:50, Angelini 
Pharma Inc., Gaithersburg, MD, USA) such as the laminar 
flow hoods, syringe pumps, and phone handsets. In one 
hospital, hazardous drugs were reconstituted and prepared 
with a Diana Hazardous Drug Compounding System (ICU 
Medical Inc., San Clemente, CA, USA), a needle-free, 
user-controlled automated compounding system. The 
centralised AD preparation units, protected by an anteroom, 
were all equipped with four IIA2-class biological safety 
cabinets.
The levels of CP, 5-FU, IP, MT, GEM, EPI, PTX, DTX, 
VNC, VNB, ETP, CTB, IRT, dacarbazine (DC), mitomycin 
C (MITC), doxorubicin (DXR), topotecan (TPT), melphalan 
(MP), idarubicine (IDC), fotemustine (FTM), and Pt – as 
a marker of cis -, carbo-, and oxaliplatin – were all measured 
in each wipe sample (altogether 74,565 measurements). 
Trophosphamide, daunorubicin, cephalomannine and 
5-chlorouracil were chosen as internal standards for liquid 
chromatography (LC)-triple quadrupole mass spectrometry 
(MS/MS) quantification.
Wipe sampling
Wipe samples were collected from the preparation and 
administration units at the beginning (B-WS) and at the end 
of the work shift (E-WS). When possible, the samples were 
also collected in the middle of the shift. We used a 
standardised kit, which comprises all the necessary tools 
(Figure 1): 5x5 cm, 3-layer nonwoven fabric wipes (Cat. 
No. 26015Y, 6-layer Luxor-Net, STS Medical Group Luigi 
Salvadori, Scandicci, Italy) wetted with 500 µL of an 
equimolar water/methanol solution, stored in a wipe 
cartridge kit (WCK) (Figure 2) developed by Chromline 
(Prato, Italy), assembled with 0.2 µm GHP Acrodisc 13 mm 
filters (Cat. No. PN4567, Pall Corporation, New York, NY, 
USA) and connected to a 2 mL vial by a joint, tweezers 
with a joint for disposable pipette tips, as well as a precise 
instruction manual with photos and a video on the correct 
technique for obtaining wipe samples.
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Table 1 Number of wipe samplings on each surface in the preparation and administration units
Preparation units Administration units
B-WS E-WS ⅀ B-WS E-WS ⅀ Total
Floor 142 138 280 468 384 852 1132
Door handle 228 254 482 303 293 596 1078
Bed area N/A N/A 419 319 738 738
Laminar flow hood 338 309 647 N/A N/A 647
WC N/A N/A 80 65 145 145
Other surfaces 180 194 374 349 351 700 1074
Total 888 895 1783 1619 1412 3031 4814
B-WS = before the work shift; E-WS = end of the work shift; ⅀ = sum of B-WS and E-WS values; N/A = not-applicable
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placed inside the WCK in off-line mode using Automated 
Wipe Desorption (Chromline, Prato, Italy) installed on a 
Flex GC autosampler (EST Analytical, Fairfield, USA) 
equipped with two 50-position WCK trays and a 2.5 mL 
headspace syringe.
Analytical procedures
The twenty ADs were quantitated with a LC-MS/MS 
(Alliance e2695/Quattro Micro API, Waters, Milford, USA) 
using fragment ions produced via collision-induced 
fragmentation. 5-FU, DC, GEM, and CTB were analysed 
with a SeQuant ZIC-HILIC, 5 µm, 200 Å 2.1x100 mm 
column (Cat. No. 1.50452.0001, Merck KGaA, Darmstadt, 
Germany) at 50 °C using 0.1 mol L-1 ammonium formate 
(A) and acetonitrile (B). The elution gradient used was the 
following: 0 min, 100 % B; 1.0 min, 80 % B; 10.0 min, 
70 % B; 12.0 min, 90 % B; 15.0 min, 100 % B. The other 
ADs were separated with an Atlantis T3, 3 µm 2.1x100 mm 
column (Cat. No. 186003718, Waters, Milford, USA) at 
25 °C with a 0.1 % formic acid solution (A) and a 0.1 % 
formic acid in 60:40 acetonitrile:methanol solution (B) for 
the gradient (0.0-2.0 min, 5 % B; 2.1-17.0 min, 85 % B; 
17.1-20.5 min, 85 % B). For both chromatographic profiles 
the flow rate was 0.3 mL min-1 with 10.0 µL of desorbed 
wipe injected into both columns. The MS utilised multiple 
reaction monitoring (MRM) for positive- and negative-ion 
On plain surfaces in the drug preparation and 
administration units (floors, laminar flow hoods, and other 
surfaces) (Table 1) an area of 20x20 cm was wiped with 
tweezers in three standard directions (down, left, and right), 
whereas the surfaces smaller than 20x20 cm were wiped in 
the same way but the exact area was recorded.
The wipe with 1.8 mL of equimolar water/methanol 
solution containing 20 ng mL-1 of internal standards, was 
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Figure 1 Wipe sampling kit: 1) wheel-trolley; 2) wipe cartridge kit (WCK) used for automatic desorption, preassembled with 5x5 cm, 
3-layer nonwoven fabric; 3) 50-position WCK trays; 4) personal computer; 5) barcode reader; 6) CD instruction manual with photos 
and a video on the correct technique for obtaining wipe samples; 7) tweezer tip waste container) 8) tweezer tips; 9) 5x5 cm, 3-layer 
nonwoven fabric and tweezers with disposable tips
Figure 2 Wipe cartridge kit (WCK): 1) 5x5 cm, 3-layer nonwoven 
fabric; 2) 2 mL vial; 3) joint; 4) 0.2 µm GHP Acrodisc 13-mm 
filters; 5) cartridge; and 6) cartridge plunger with a hole for a 
2.5 mL syringe
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electrospray ionization (ESI+, ESI-) acquisition windows 
(Figure 3).
Pt was analysed with an iCAPQ inductively coupled 
plasma (ICP)-MS (Thermo Fisher Scientific, Waltham, MA, 
USA) with a Cetac ASX520 autosampler (Cetac 
Technologies, Omaha, NE, USA), a PFA cyclonic spray 
chamber, and a 2.5-mm internal-diameter quartz injector. 
Pt levels were measured in the standard mode (STD), as follows: 
1:20 dilution of wipe extraction solution with 1 % hydrochloric 
acid; peristaltic pump speed: 40 rpm; nebuliser gas flow rate: 
0.91 L min-1; radio frequency power: 1.550 W; cool gas flow: 
14 L min-1; and auxiliary gas flow: 0.89 L min-1. Dwell times 
were 50 ms for 194Pt and 10 ms for internal standards, with 
40 sweeps per replicate and three replicates per sample. 
Moreover, dwell times for 114In were 1.0 s, and 0.05 s for 
72Ge, with 20 sweeps per replicate and three replicates per 
sample. The instrument was tuned daily to ensure 
optimisation.
Blank wipe samples and wipe samples spiked with the 
internal standard solution alone or with six calibration 
standards obtained from a mixed solution of all 21 ADs, 
were used to build a calibration curve at the following 
concentrations: 1.25, 2.5, 5.0, 10.0, 20.0, 40 ng per wipe. 
Five replicates for every standard were analysed, and the 
peak area ratio from each analyte and internal standard used 
to obtain the response factor plot. The slopes (m) and 
intercepts (b) of the calibration lines were estimated with 
the least-square linear regression analysis, using the 
following formula:
y=mx+b
where y is the ratio between the chromatographic area 
of the analyte and its internal standard, and x is the 
concentration of the analyte.
The limit of detection (LOD) was calculated according 
to the formula:
LOD=(3SEb+b)/m
where SEb is the standard error of the intercept.
The lower limit of quantification (LOQ) was then 
estimated in the same way using 10SEb, which corresponds 
to 3.3 LOD.
The precision of the assay (as a coefficient of variation, 
CV %) was estimated both as within-session and as inter-
session repeatability.
Within-session accuracy was evaluated by recoveries 
(reported as the percentage ratio between the measured and 
the nominal concentrations) at all concentrations used for 
the calibration plot (Table 2). These accuracy values were 
Figure 3 LC-MS/MS chromatograms of ADs standard at 1.25 ng mL-1 performed by Atlantis T3 (3a, 3b, 3c) and ZIC-HILIC (3d) columns. 
Four acquisition windows in MRM mode, with positive- and negative-ion electrospray ionization show retention time and area peak




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































then compared with the US Food and Drug Administration 
requirements in order to validate our analytical methods.
Low (2 ng mL-1) and high (20 ng mL-1) level quality 
control samples (QCs) were prepared and processed in every 
analytical session from a fresh solution with 21 ADs with 
internal standards to ensure the intra- and inter-day 
repeatability of reported results.
Validation study
The wiping recoveries of each AD were evaluated in 
terms of the percentage of removal efficiency from spiked 
surfaces. To do that, we quantified additional wipe samples 
taken from stainless steel, smooth (non-porous 
polycarbonate) and less smooth (polyvinyl chloride 
flooring), 20x20 cm brand new plates spiked to 20 ng 
(50 pg cm-2) and 100 ng (250 pg cm-2) of AD. Spiked wipe 
sample stability was tested at 4 °C from 4 to 24 h.
The desorption efficiencies were calculated as the 
percentage of response decline between the spiked wipes 
and the nominal AD solution analysed.
We also established the MS matrix effects in six 
replicates for each AD in terms of mean relative ionisation 
recovery for the analytes, calculated as the percentage of 
response decline between the analytes spiked into the eluate, 
obtained after extracting the blank wipe, and the analytes 
injected directly into the mobile phase.
The obtained data management were processed with 
the Stata data analysis and statistical software (StataCorp 
LLC, College Station, TX, USA).
RESULTS
Wiping and desorption
Our wiping procedure, with tweezers instead of a new 
pair of gloves as other authors do, reduced the sampling 
time (15 s per wiping), cost (as the price of the replaceable 
tweezer tips is much lower than that of gloves), and the risk 
of contamination, and the recoveries were over 75 % (Table 
2). The full insertion of the wipes into the holder and 
automation ensured desorption efficiencies close to 100 % 
for all ADs. The filling speed for the 2.5 mL syringe was 
set to 30 µL s-1.
Analyses
Analytical curves were linear over the entire 
concentration range, with correlation coefficients (r2) above 
0.992 for all tested compounds. As the intra- and inter-day 
variability for all compounds ranged from 0.9-6.8 %, the 
average accuracy and inter-day precision were within the 
acceptable range. The LOQs for wipe ADs were between 
0.06 and 3.49 ng wipe-1 (Table 2).
Data distribution
Of the 4,814 wipes taken 1,583 (604 in preparation units 
and 979 in administration units) were ≥LOQ (33 %). Of 
these, 775 were taken before and 808 after the work shift.
Table 3 shows that of the 74,565 measurements, positive 
were 3,081 (1399 in preparation units and 1682 in 
administration units) or 4.1 %. Positive measurements for 
at least one AD before and after the work shift were 1,399 
and 1,682, respectively. Most of them were determined on 
samples taken from “other surfaces” (waste containers, 
personal computers, support surfaces, intercoms, phones, 
and chairs), followed by the floors (23.2 %), laminar flow 
hoods (19.1 %), door handles (16.7 %), and what is referred 
to as “the bed area” (the bed, armchairs, drip shaft, and 
syringe pump) (9.8 %).
The six most frequently detected substances were CP 
(17.2 % of all CP measurements were positive), IP (15.4 % 
of all IP measurements were positive), GEM (8.6 %), Pt 
(5.4 %), and 5-FU (4.4 %), and PTX (4.1 %).
Table 4 shows the number of measurements ≥LOQ as 
well as ranges by ADs.
Surface exposure levels
Because the values obtained showed a strongly skewed 
distribution, we decided to classify the data by the 90th and 
the 75th percentile instead of using normal distribution 
parameters. Table 5 shows the proposed limit surface 
exposure levels (SELs) for CP, IP, GEM, PTX, 5-FU, and 
Pt, expressed in pg cm-2 and derived from the percentiles 
of contamination levels for different categories of surfaces. 
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Table 3 Positive findings of at least one AD on workplace surfaces
Preparation units Administration units
B-WS E-WS ⅀ B-WS E-WS ⅀ Total
Floor 70 73 143 266 307 573 716
Door handle 114 147 261 130 124 254 515
Bed area N/A N/A N/A 160 144 304 304
Laminar flow hood 293 296 589 N/A N/A 589
WC N/A N/A 63 69 132 132
Other surfaces 179 227 406 206 213 419 825
Total 656 743 1399 825 857 1682 3081
B-WS = before the work shift; E-WS = end of the work shift; ⅀ = sum of B-WS and E-WS values; N/A = not-applicable
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These limits were actually adopted by all the nine 
participating hospital pharmacies and administration units 
for good hygiene practice. For all other ADs, the analysed 
50th, 75th, and 90th percentiles were lower than our LOQs.
DISCUSSION
Current analytical methods for biological monitoring 
are not sensitive or specific enough for ADs (12, 29, 30). 
With modern ventilation resources at hand AD inhalation 
has become controlled and air sampling will soon be useless, 
which begs the question: which new validated environmental 
monitoring method will replace it. We recommend the wipe 
test, a method widely used by industrial hygienists and 
currently the only one able to detect ADs at levels as low 
as pg cm-2.
The actual risk to healthcare workers depends on AD 
toxicity and how these drugs enter the body; this should 
guide its handling protocols. In general, dermal absorption 
is more likely to occur with drugs with a molecular weight 
of <500 Da and less likely for those >1000 Da (31-34). The 
Occupational Safety and Health Administration (35), United 
States Pharmacopeia (36) and the European Parliament 
Policy Recommendation (37) all suggest adopting an 
environmental monitoring program for ADs and using tools 
that facilitate easy interpretation of these results. Our 
procedure, as outlined in this paper, both monitors AD 
contamination of healthcare environment and reliably 
measures cleaning effectiveness and worker adherence to 
protocols.
The development of chromatographic methods for 
simultaneous analysis of polar and non-polar compounds 
has piqued the interest of the international scientific 
community (38), including our research group. More 
specifically, some authors (13-15, 21) have proposed LC 
methods for 5-FU resolution via a C18 stationary phase 
combining hydrophobic and polar selectivity. Since our 
goal was to analyse as many ADs as possible at the same 
time, given that cancer treatments often include more than 
one cytotoxic drug and that this increases the probability 
of having at least one positive finding, we preferred to use 
two LC columns: one for hydrophobic cytostatic drugs and 
one for the hydrophilic ones. The former employs Atlantis 
T3 columns: silica-based, reversed-phase C18 columns that 
provide balanced retention of low-polar and hydrophobic 
molecules. Their T3 bonding utilises a trifunctional C18 
alkyl phase with a ligand density that promotes polar 
compound retention and aqueous mobile phase compatibility. 
The second, utilises the SeQuant ZIC-hydrophilic 
interaction liquid chromatography (HILIC) to separate polar 
and hydrophilic compounds, and its high-performance, 
Table 4 Measurements for each AD and related minimum and maximum concentration values
Number of meas-
urements
Number of positive 
measurements








DC 4,701 70 1.5 0.8 8,175
GEM 4,934 425 8.6 0.8 138,453
MT 3,329 28 0.8 2 27,387
MITC 4,569 12 0.3 2.8 463
IRT 4,934 98 2.0 0.8 49,553
VNC 3,341 17 0.5 2.5 416
VNB 669 20 3.0 1.2 279
EPI 4,934 27 0.5 1.2 1,364
DXR 4,701 35 0.7 3 1,181
CP 5,025 864 17.2 2 78,075
IP 4,934 762 15.4 1.8 214,628
ETP 4,904 27 0.6 3 1920
DTX 4,702 74 1.6 1.2 27,478
PTX 4,934 201 4.1 0.8 11,635
TPT 179 0 0.0 0 ---
MP 1,481 0 0.0 0 ---
IDC 2,513 27 1.1 4 1,485
CTB 1,877 30 1.6 4 254,3
FTM 320 2 0.6 2.4 ---
5-FU 4,586 201 4.4 3 236,097
Pt 2,998 161 5.4 0.1 2,851
Total 74,565 3,081




























































































































































































































































































































































































































































































































































































zwitterionic stationary phase ensures reproducible retention 
of 5-FU, DC, and CTB which would otherwise have poor 
retention and are difficult to separate on reversed-phase LC 
columns. Simply put, HILIC is a normal-phase type of 
separation, but it can use reversed-phase type eluents. In 
recent years, it has received a lot of attention (39). The 
Three-Column Selector Valve developed by Waters has 
made possible automated switching of the two analytical 
columns between one analysis and the other. As a result of 
these innovations, we were able to come up with a novel 
LC-MS/MS approach capable of detecting twenty ADs. 
The off-line xyz robotic system allows for automated 
consecutive wipe desorption without the need for manual 
operation. The WCK barcodes provided each wipe with a 
unique assembly tracking number for traceability. 
Furthermore, flexible profile monitoring enabled us to 
integrate all sampling management, data analysing 
processes, and software into the Bika Laboratory 
Information Management Systems (LIMS).
No governmental industrial hygiene association has yet 
set exposure limits for ADs since no safe exposure levels 
are known. Instead, the most commonly applied principle 
is “As Low As Reasonably Achievable” (ALARA), but 
interventions to reduce exposure as much as possible cannot 
be verified without quantitative evidence of environmental 
contamination. Perhaps the only environment where AD 
exposure can be monitored and limited is the workplace, 
and it is therefore imperative to do that. Furthermore, in 
agreement with Kromhout (40), we strongly support 
quantitative assessment of AD exposure, as it ensures better 
accuracy of exposure estimates in occupational and 
domestic settings.
Ubiquitous environmental contamination with ADs is 
the consequence of their massive use. There is hardly a 
hospital not handling them, which inevitably leads to the 
contamination of drug containers and cross-contamination 
of cytotoxic drug vials (41-44). Furthermore, patients carry 
contamination home (45), and eventually it reaches water 
(46). The SELs we propose take into account different 
aspects of AD contamination that may occur in the 
healthcare environment: from contamination with pure drug 
in the preparation units to contamination with its diluted 
and biological (e.g. urine, saliva, sweat) forms in the 
administration units at the beginning and end of the work 
shift (i. e. when the workplace is expected to be clean and 
when it is not). Their purpose is to verify worker compliance 
with procedures, cleaning efficacy, and persistence of 
pollution over time. Our SELs are in line with the TGVs 
proposed by Böhlandt and Schierl (26) for 5-FU and Pt, the 
HGVs indicated by Hedmer and Wohlfart (27) for CP and 
IP, and with the cytotoxic-independent target value of 
100 pg cm-2 proposed by Kiffmeyer et al. (22), based on the 
90th percentile of the results.
We have therefore created a traffic-light colour-coding 
system for 21 ADs, where values between the LOQ and the 
75th percentile are coloured green, between the 75th and the 
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90th percentile amber, and above the 90th percentile red for 
user-friendly monitoring in healthcare environment at the 
beginning and at the end of the work shift. Table 6 illustrates 
the colour-coding system used by an AD pharmacy 
preparation unit in monitoring reports.
They will help in interpreting monitoring results, that 
is, until official threshold limits have been defined. In 
addition, this could facilitate comparison with other 
countries in order to extend the database and identify the 
best practices for handling drugs under different workplace 
conditions.
As for the wipe-sampling approach described in this 
study, we believe it can also be applied to other relevant 
substances, such as monoclonal antibodies and antibiotics 
on NIOSH’s recent list of hazardous drugs.
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Novi pristup procjeni profesionalne izloženosti antineoplasticima u bolničkom okruženju
Zbog profesionalnih rizika koje donose, s citotoksičnim antineoplasticima potrebno je sigurno rukovati. U ovom članku 
predstavljamo validirani inovativan protokol kojim se istodobno mogu pratiti razine dvadeset jednog antineoplastika u 
zdravstvenim ustanovama te predlažemo razine površinske izloženosti (engl. surface exposure levels, krat. SELs) koje bi 
trebale olakšati tumačenje dobivenih rezultata praćenja, budući da trenutačno nisu propisane granične vrijednosti 
profesionalne izloženosti antineoplasticima. Rezultate praćenja onečišćenja antineoplasticima prikupili smo od devet 
talijanskih bolnica od 2008. do 2017., a obuhvaćaju 74.565 mjerenja 4.814 uzoraka prikupljenih brisanjem površina 
namjenskim maramicama (brisom). Ovakav je protokol upravo zbog izvrsne iskorištenosti i osjetljivosti analitičkih metoda 
te inovativne automatizacije desorpcije pogodan za rutinsko praćenje izloženosti u bolničkom okruženju. Onečišćenje 
antineoplasticima utvrđeno je u 3.081 mjerenju, što potvrđuje rizik od izloženosti u zdravstvenih radnika. Uzimanjem 
uzoraka na početku i kraju radne smjene omogućen je izračun vrijednosti unutar 75. i 90. percentila za svaki antineoplastik 
za jedinice u kojima se oni pripremaju i primjenjuju. Na temelju tih izračuna osmislili smo semaforski sustav boja koji 
olakšava tumačenje rezultata, a predložene razine površinske izloženosti poslužit će kao dobar temelj za poboljšanje 
sigurnosti na radnome mjestu i smanjenje onečišćenja.
KLJUČNE RIJEČI: bris test; masena spektrometrija s induktivno spregnutom plazmom; masena spektrometrija s 
tekućinskom kromatografijom; onečišćenje površina; zaštita na radu
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